A case of follicular lymphoma associated with paraneoplastic cerebellar degeneration.
Paraneoplastic neurological disorders (PND) are neurological effects of malignancy that are recognized as immune-mediated disorders caused by aberrant expression of a tumor antigen that is normally expressed in the nervous system. We report a case of cerebellar ataxia which turned out to be paraneoplastic cerebellar degeneration, a subtype of PND that develops cerebellar symptoms, that was caused by follicular lymphoma. After chemotherapy, the patient attained sufficient improvement of cerebellar symptoms along with complete remission of lymphoma. Paraneoplastic cerebellar degeneration should be recognized as a rare complication of lymphoma as it is important to start proper treatment before the neurological symptoms become irreversible.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Japan.
Yayoi
Y
Shimazu
Eiko N
EN
Minakawa
Momoko
M
Nishikori
Masafumi
M
Ihara
Yuichiro
Y
Hashi
Hirofumi
H
Matsuyama
Masakatsu
M
Hishizawa
Sonoyo
S
Yoshida
Toshiyuki
T
Kitano
Tadakazu
T
Kondo
Takayuki
T
Ishikawa
Ryosuke
R
Takahashi
Akifumi
A
Takaori-Kondo
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000951:Antigens, Neoplasm / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008224:Lymphoma, Follicular / Q000150:complications* / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D020362:Paraneoplastic Cerebellar Degeneration / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D011241:Prednisone / Q000008:administration & dosage; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D012074:Remission Induction; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm; D015375:Receptors, Interleukin-2; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone